Literature DB >> 25751015

Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen.

Genevieve Clutton1, Anne Bridgeman, Arturo Reyes-Sandoval, Tomas Hanke, Lucy Dorrell.   

Abstract

Viral vector vaccines designed to elicit CD8(+) T cells in non-human primates exert potent control of immunodeficiency virus infections; however, similar approaches have been unsuccessful in humans. Adenoviral vectors elicit potent T cell responses but also induce production of immunosuppressive interleukin-10 (IL-10), which can limit the expansion of T cell responses. We investigated whether inhibiting IL-10 signaling prior to immunization with a candidate adenovirus vectored-HIV-1 vaccine, ChAdV63.HIVconsv, could modulate innate and adaptive immune responses in BALB/c mice. Transient IL-10 receptor blockade led to a modest but significant increase in the total magnitude CD8(+) T cell response to HIVconsv, but did not affect T cell responses to immunodominant epitopes. Anti-IL-10R-treated animals also exhibited greater expression of CD86 on CD11c(+) dendritic cells. Our data support further investigation and optimization of IL-10 blocking strategies to improve the immunogenicity of vaccines based on replication-defective adenoviruses.

Entities:  

Keywords:  HIV-1; T cells; interleukin-10; mouse

Mesh:

Substances:

Year:  2015        PMID: 25751015      PMCID: PMC4514343          DOI: 10.1080/21645515.2015.1009809

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  21 in total

1.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo.

Authors:  K M Kopydlowski; C A Salkowski; M J Cody; N van Rooijen; J Major; T A Hamilton; S N Vogel
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

3.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Authors:  Frances H Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

4.  Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression.

Authors:  R S Mitra; T A Judge; F O Nestle; L A Turka; B J Nickoloff
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

5.  Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice.

Authors:  Eung-Jun Im; Tomás Hanke
Journal:  AIDS Res Hum Retroviruses       Date:  2007-07       Impact factor: 2.205

6.  IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection.

Authors:  David G Brooks; Andrew M Lee; Heidi Elsaesser; Dorian B McGavern; Michael B A Oldstone
Journal:  J Exp Med       Date:  2008-03-10       Impact factor: 14.307

7.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

8.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

9.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

Review 10.  Adenoviruses as vaccine vectors.

Authors:  Nia Tatsis; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2004-10       Impact factor: 11.454

View more
  4 in total

1.  [Value of heparin-binding protein in the diagnosis of severe adenovirus pneumonia in children].

Authors:  Xiao-Yan Liu; Xiao-Fo Zhang; Jia Li; Fang Zhu; Qing-Le Yu; Song-Qing Wei; Man-Zhi Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022 Sept 15

2.  Investigation the Possibility of Using Peptides with a Helical Repeating Pattern of Hydro-Phobic and Hydrophilic Residues to Inhibit IL-10.

Authors:  Guoying Ni; Shu Chen; Yuedong Yang; Scott F Cummins; Jian Zhan; Zhixiu Li; Bin Zhu; Kate Mounsey; Shelley Walton; Ming Q Wei; Yuejian Wang; Yaoqi Zhou; Tianfang Wang; Xiaosong Liu
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

3.  Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA.

Authors:  Nathifa Moyo; Annette B Vogel; Søren Buus; Stephanie Erbar; Edmund G Wee; Ugur Sahin; Tomáš Hanke
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-26       Impact factor: 6.698

4.  Blocking IL-10 signaling with soluble IL-10 receptor restores in vitro specific lymphoproliferative response in dogs with leishmaniasis caused by Leishmania infantum.

Authors:  Catiule de Oliveira Santos; Sidnei Ferro Costa; Fabiana Santana Souza; Jessica Mariane Ferreira Mendes; Cristiane Garboggini Melo de Pinheiro; Diogo Rodrigo de Magalhães Moreira; Luciano Kalabric Silva; Valeria Marçal Felix de Lima; Geraldo Gileno de Sá Oliveira
Journal:  PLoS One       Date:  2021-01-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.